Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140962 | 1.00 | SLC6A2 (0.53) | SLC6A2PDE4DTSHRKDM4EPOLB | |
| SCHEMBL31081717 | 1.00 | SLC6A2 (0.53) | SLC6A2PDE4DTSHRKDM4EPOLB | |
| SCHEMBL7349197 | 1.00 | SLC6A2 (0.53) | SLC6A2PDE4DTSHRKDM4EPOLB | |
| SCHEMBL15498506 | 1.00 | SLC6A2 (0.53) | SLC6A2PDE4DTSHRKDM4EPOLB | |
| SCHEMBL7344189 | 1.00 | SLC6A2 (0.53) | SLC6A2PDE4DTSHRKDM4EPOLB | |
| SCHEMBL4140963 | 1.00 | SLC6A2 (0.53) | SLC6A2PDE4DTSHRKDM4EPOLB | |
| SCHEMBL8662256 | 1.00 | SLC6A2 (0.53) | SLC6A2PDE4DTSHRKDM4EPOLB | |
| SCHEMBL24215035 | 0.90 | TSHR (0.61) | SLC6A2PDE4DTSHRTAAR1LMNA | |
| SCHEMBL9679098 | 0.90 | TSHR (0.61) | SLC6A2PDE4DTSHRTAAR1LMNA | |
| SCHEMBL13941992 | 0.90 | TSHR (0.61) | SLC6A2PDE4DTSHRTAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | SLC6A2 789/4885PDE4D 293/4885TSHR 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.